ChemoCentryx Reports CCX140B Meets Primary Endpoint and Demonstrates Clinical Efficacy in Phase II Study in Type 2 Diabetes

MOUNTAIN VIEW Calif. Sept. 15 2011 PRNewswire ChemoCentryx Inc. today announced that the Company's novel orally active CCR2 antagonist CCX140B demonstrated an excellent safety profile and exhibited clear signs of biological and clinical effect in a Phase ...